Onabotulinumtoxina Re-Injection for Refractory Detrusor Overactivity Using 3-4 Injection Sites: Results of A Pilot Study.

[1]  R. O'Connor,et al.  Less is more—A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity , 2017, Neurourology and urodynamics.

[2]  G. Karsenty,et al.  Efficacy and safety of two administration modes of an intra‐detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo‐controlled phase IIa study , 2017, Neurourology and urodynamics.

[3]  V. Nitti,et al.  Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. , 2016, The Journal of urology.

[4]  K. Jünemann,et al.  Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. , 2016, The Journal of urology.

[5]  C. Liao,et al.  Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study , 2016, Neurourology and urodynamics.

[6]  Po-Fan Hsieh,et al.  Botulinum toxin A for the Treatment of Overactive Bladder , 2016, Toxins.

[7]  P. Rebollo,et al.  The 3‐day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women , 2015, Neurourology and urodynamics.

[8]  J. Alcañiz,et al.  OnabotulinumtoxinA injections for idiopathic and neurogenic overactive bladder: discontinuation rates and reasons for treatment disruption , 2015 .

[9]  P. Dasgupta,et al.  An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. , 2014, European urology.

[10]  C. Nardo,et al.  OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder , 2014, International journal of clinical practice.

[11]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[12]  G. Karsenty,et al.  Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. , 2013, Urology.

[13]  J. Rejas,et al.  [Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder]. , 2013, Medicina clinica.

[14]  F. Cruz,et al.  Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. , 2012, European urology.

[15]  M. Brin,et al.  Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. , 2011, European urology.

[16]  S. Colman,et al.  Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. , 2008, Urology.

[17]  B. Schurch,et al.  890 BOTULINUM TOXIN-A (BTA) IN THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY INCONTINENCE (NDOI) -A PROSPECTIVE RANDOMIZED STUDY TO COMPARE 30 VS. 10 INJECTION SITES , 2007 .